Reamberine, 1.5% 400 ml

Pharmacotherapeutic group: solutions affecting water-electrolyte balance.

The ATX code: B05BB

Pharmacological properties

Pharmacodynamics

REAMBERIN® has antihypoxic and antioxidant effects with a positive effect on aerobic processes in the cell, reducing free radical production and restoring energy potential of cells.

The drug activates the enzymatic processes of the Krebs cycle and promotes the utilization of fatty acids and glucose in cells, normalizes the acid-base balance and blood gas composition. It has a moderate diuretic effect.

Pharmacokinetics

In intravenous administration the drug is quickly utilized and does not accumulate in the body.

Indications

REAMBERIN® is used in adults and children from 1 year of age as an antihypoxic and detoxifying agent for acute endogenous and exogenous intoxications of various etiologies.

Pharmacological effect

Pharmacotherapeutic group: solutions affecting water and electrolyte balance.

ATX code: В05ВВ

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics

REAMBERIN® has an antihypoxic and antioxidant effect, having a positive effect on aerobic processes in the cell, reducing the production of free radicals and restoring the energy potential of cells.

The drug activates the enzymatic processes of the Krebs cycle and promotes the utilization of fatty acids and glucose by cells, normalizes the acid-base balance and gas composition of the blood. Has a moderate diuretic effect.

Pharmacokinetics

When administered intravenously, the drug is quickly utilized and does not accumulate in the body.

Special instructions

Due to the activation of aerobic processes in the body by the drug, a decrease in the concentration of glucose in the blood and the appearance of an alkaline reaction in urine are possible. In patients with diabetes mellitus and patients with reduced glucose tolerance, periodic monitoring of blood glucose concentrations is required. If the color of the solution changes or there is a precipitate, the use of the drug is unacceptable.

Effect on the ability to drive vehicles and machinery It is not recommended to drive vehicles or operate machinery during a course of treatment with REAMBERIN®.

Active ingredient

Meglumine sodium succinate

Composition

Active ingredient: sodium meglumine succinate – 15.00 g.

Excipients: sodium chloride – 6.00 g, potassium chloride – 0.30 g, magnesium chloride hexahydrate (in terms of anhydrous) – 0.12 g, sodium hydroxide – 1.788 g, succinic acid – to pH from 6.0 to 7.0, water for injection – up to 1.0 l.

Ionic composition per 1 l:

– sodium 147 mmol
– potassium 4.02 mmol
– magnesium 1.26 mmol
– chlorides 109 mmol
– succinates 46.0 mmol
– meglumine 44.7 mmol

Theoretical osmolarity 353 mOsm/l

Pregnancy

The drug is contraindicated for use during pregnancy and lactation.

Contraindications

Adults: administered intravenously at a rate of 1–4.5 ml/min (up to 90 drops per minute). The average daily dose is 10 ml/kg. The course of therapy is up to 11 days.

Children: administered intravenously at a rate of 6–10 ml/kg per day at a rate of 3–4 ml/min. The course of therapy is up to 11 days.

Use in elderly patients. No studies have been conducted in elderly patients. In this regard, the use of the drug should be started with a slower rate of administration: 20–40 drops (1–2 ml) per minute.

Use in patients with renal failure. No studies have been conducted in patients with renal failure. In this regard, it is recommended to exercise caution when using the drug in such patients.

Use for alkalosis. If decompensated alkalosis is detected, the use of the drug should be discontinued until the acid-base state of the blood normalizes.

Side Effects

According to the World Health Organization, adverse effects are classified according to their frequency as follows:

– very frequent (≥ 1/10);
– frequent (from ≥ 1/100 to < 1/10);
– infrequent (from ≥ 1/1000 to < 1/100);
– rare (from ≥ 1/10000 to < 1/1000);
– very rare (< 1/10000);
– frequency unknown (cannot be determined based on available data).

If the drug is administered quickly, undesirable effects are possible.

General disorders and disorders at the injection site: very rarely – hyperthermia, chills, sweating, weakness, pain at the injection site, edema, hyperemia, phlebitis.

Immune system disorders: very rarely – allergic reactions, angioedema, anaphylactic shock.

Disorders of the skin and subcutaneous tissues: very rarely – allergic rash, urticaria, itching.

Disorders of the respiratory system, chest and mediastinal organs: very rarely – shortness of breath, dry cough.

Cardiac disorders: very rarely – tachycardia, palpitations, shortness of breath, pain in the heart, chest pain.

Vascular disorders: very rarely – arterial hypotension/hypertension, short-term reactions in the form of a burning sensation and redness of the upper body.

Gastrointestinal disorders: very rarely – nausea, vomiting, metallic taste in the mouth, abdominal pain, diarrhea.

Nervous system disorders: very rarely – dizziness, headache, convulsions, tremor, paresthesia, agitation, anxiety.

To avoid the occurrence of undesirable effects, it is recommended to adhere to the dosage regimen and rate of administration of the drug.

If adverse reactions occur, it is recommended to reduce the rate of drug administration.

If any of the undesirable effects indicated in the instructions worsen or you notice any other undesirable effects not listed in the instructions, tell your doctor.

Interaction

The drug combines well with antibiotics, water-soluble vitamins, and glucose solution. Combined with drugs containing phosphates, sulfates or tartrates. It is not recommended to mix it in the bottle or container with other medications. Intravenous administration of REAMBERIN® simultaneously with calcium preparations is unacceptable due to possible precipitation of calcium succinate.

Overdose

Data on overdose of the drug Reamberin are not provided.

Storage conditions

In a place protected from light at a temperature not exceeding 25 ° C. Freezing of the drug is allowed. Keep out of the reach of children.

Shelf life

5 years in glass bottles, 3 years in polymer containers made of multilayer polyolefin film. Do not use after the expiration date stated on the package.

Manufacturer

Polisan NTFF LLC, Russia